Momenta Pharmaceuticals VP Unloads $81,119 in Stock (MNTA)
Momenta Pharmaceuticals (NASDAQ:MNTA) VP John Bishop sold 5,247 shares of the stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $15.46, for a total transaction of $81,118.62. Following the completion of the sale, the vice president now directly owns 94,618 shares of the company’s stock, valued at approximately $1,462,794. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) traded down 1.02% on Tuesday, hitting $15.53. The stock had a trading volume of 145,848 shares. Momenta Pharmaceuticals has a 52 week low of $10.05 and a 52 week high of $18.08. The stock’s 50-day moving average is $15.0 and its 200-day moving average is $14.31. The company’s market cap is $789.1 million.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.57) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.45) by $0.12. The company had revenue of $4.40 million for the quarter, compared to the consensus estimate of $8.85 million. During the same quarter in the prior year, the company posted ($0.20) earnings per share. The company’s quarterly revenue was down 79.9% on a year-over-year basis. On average, analysts predict that Momenta Pharmaceuticals will post $-2.01 earnings per share for the current fiscal year.
A number of research firms have recently commented on MNTA. Analysts at R. F. Lafferty initiated coverage on shares of Momenta Pharmaceuticals in a research note to investors on Monday. They set a “buy” rating and a $19.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note to investors on Wednesday, October 9th. Finally, analysts at Canaccord Genuity raised their price target on shares of Momenta Pharmaceuticals from $13.00 to $22.00 in a research note to investors on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $18.17.
Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.